We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

RUBI:NASDAQRubico Inc. Analysis

Data as of 2026-05-29 - not real-time

$0.59

Latest Price

8/10Risk

Risk Level: High

Executive Summary

Rubico Inc. (RUBI) is trading at $0.59, essentially hugging its 20‑day support of $0.5808 and well below its 20‑day SMA of $1.86, indicating a deep discount. The RSI of 14.97 flags an oversold condition, while the MACD histogram (+0.11) and bullish signal suggest short‑term momentum may be turning positive. Volume is on an increasing trend, providing some liquidity support despite the company’s modest market cap of roughly $1.9 M. However, the fundamentals are strained: revenue is declining (-5.1%), debt totals $82.3 M versus just $4 M in cash, and the debt‑to‑equity ratio sits at an alarming 179, driving a max drawdown near -100%. The DCF model places fair value at $13.43, implying the stock is severely undervalued relative to its intrinsic estimate. Recent material news includes a reverse stock split and a $5 M public offering, which may dilute existing shareholders but also provide needed capital. Overall, the stock sits at the intersection of extreme price weakness, high volatility (192% 30‑day), and significant balance‑sheet risk, creating a high‑risk, high‑potential scenario.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 6/10

Key Factors

  • Oversold RSI well below 30 indicating potential rebound
  • Bullish MACD histogram suggesting upward momentum
  • Increasing trading volume supporting short‑term price support

Medium Term

1–3 years
Neutral
Model confidence: 4/10

Key Factors

  • High leverage with debt‑to‑equity > 170 and negative revenue growth
  • Extreme price volatility and thin market capitalization
  • Uncertainty surrounding recent reverse split and capital raise

Long Term

> 3 years
Cautious
Model confidence: 3/10

Key Factors

  • Structural financial distress and unsustainable debt levels
  • Lack of dividend and limited cash reserves
  • DCF fair value far above current price, indicating speculative upside that may not materialize

Key Metrics & Analysis

Financial Health

Revenue Growth-5.10%
Profit Margin11.24%
P/E Ratio0.0
ROE6.62%
ROA6.26%
Debt/Equity179.66
P/B Ratio0.0
Op. Cash Flow$11.3M
Free Cash Flow$9.3M
Industry P/E30.0

Technical Analysis

TrendBearish
RSI15.0
Support$0.58
Resistance$3.63
MA 20$1.86
MA 50$3.44
MA 200$1,567.38
MACDBullish
VolumeIncreasing
Fear & Greed Index93.7

Valuation

Fair Value$13.43
GradeUndervalued
TypeValue

Risk Assessment

Beta0.65
Volatility192.67%
Sector RiskHigh
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskHigh

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.